GlassScriptPhysician profile
James A Lipke
NPI 1265476923
$3,403.16
in general payments reported to CMS, 2019-2025
34 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.91 · 2023: $844 · 2024: $1,257 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,353.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $477.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $304.82 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $256.82 | 2023-2024 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $242.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $197.65 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $179.01 | 2024-2025 | Freestyle Libre 3, Freestyle Libre |
| Novo Nordisk INC | $168.77 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $159.06 | 2023-2025 | |
| Shield Therapeutics INC | $144.61 | 2025 | |
| Pfizer INC. | $138.03 | 2023-2024 | |
| Seqirus USA INC | $113.39 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Amgen INC. | $93.57 | 2023-2024 | Krystexxa, Repatha |
| Noven Therapeutics, LLC | $92.35 | 2024-2025 | Xelstrym |
| Renalytix Ai, INC. | $73.89 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Insulet Corporation | $70.20 | 2025 | Omnipod |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $68.82 | 2025 | Qutenza |
| Xeris Pharmaceuticals, INC. | $57.81 | 2023 | Gvoke Hypopen |
| Biogen, INC. | $55.02 | 2024 | Skyclarys |
| Novavax INC | $52.65 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.38 | 2025 | Caplyta |
| Baxter Healthcare | $43.11 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi Pasteur INC. | $41.12 | 2019-2025 | |
| Philips North America LLC | $40.32 | 2025 | Ecc Solutions |
| Janssen Pharmaceuticals, INC | $39.79 | 2024 | Xarelto |
| Genentech USA, INC. | $38.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.01 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $29.82 | 2023-2025 | Capvaxive, Gardasil 9, Dificid |
| Boston Scientific Corporation | $27.71 | 2024 | Wavewriter Alpha Prime 16 |
| Dexcom, INC. | $24.52 | 2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $23.60 | 2023 | Krystexxa |
| Astellas Pharma US INC | $22.42 | 2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $14.80 | 2024 | Ajovy |
| Lundbeck LLC | $13.11 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $12.83 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lipke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.